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Oxysterols are oxygenated derivatives of cholesterol characterized by a very short half-life and their 
ability to pass lipophilic membranes easily, thus they are considered as important intermediates in 
cholesterol excretion pathways and its conversion to bile acids. 
 
The two major oxysterols in the circulation of human and mouse are 24S-hydroxycholesterol (24S-
OH) and 27-hydroxycholesterol (27-OH), which are formed by the cytochrome P450 enzymes 
cholesterol 24-hydroxylase (CYP46A1) and sterol 27-hydroxylase (CYP27A1), respectively. The 
two oxysterols 27-OH and 24S-OH are both strong inhibitors of cholesterol synthesis and activators 
of LXR in vitro. However, their role as physiological regulators under in vivo conditions is 
controversial.  
 
The overall aim of this thesis was to investigate the regulatory role of side chain oxidized oxysterols 
as metabolic regulators in vivo. In particular we have studied the role of 24S-and 27-
hydroxycholesterols (24S-and 27-OH) as regulators of cholesterol synthesis and activators of LXR. 
We used mouse models with increased levels of 27-OH (CYP27A1) transgenic mice and Cyp7b1 
knock-out mice (Cyp7b1-/-) as well as a mouse model with no detectable levels of 27-OH in their 
circulation, Cyp27a1 knock-out mice (Cyp 27-/-). The latter mice were treated with cholic acid to 
compensate for the reduced formation of bile acids. 
 
In Paper I, we studied a possible regulatory role of 27-OH and 24S-OH in the brain using human 
CYP27A1 transgenic mice(CYP27A1tg) and Cyp27a1 knock-out (Cyp 27a1-/-) mice. The levels of 
27-OH were increased about 12-fold in the brain of CYP27A1tg mice while the levels of 24S-OH 
was decreased by about 25%, most probably due to increased metabolism by the CYP27A1 enzyme. 
The mRNA levels of HMG-CoA reductase and HMG-CoA synthase in the brain were increased. In 
accordance with increased cholesterol synthesis, most of cholesterol precursors were also increased. 
The increased cholesterol synthesis is likely due to reduced inhibition by 24S-OH. 27-OH is an 
activator of LXR and in spite of this, there was no upregulation of the LXR-target genes in the brain 
of the transgenic mice. In contrast, some of the genes were downregulated.  In Cyp27a1-/- mouse 
brain, cholesterol synthesis was slightly increased with increased levels of cholesterol precursors. 
The increased synthesis is probably the consequence of the absence of an inhibitory effect of the 
flux of 27-OH into the brain. The results of this study are consistent with the possibility that both 
24S-OH and 27-OH have a suppressive effect on cholesterol synthesis in the brain. Since there was 
no activation of the LXR-target genes in the brain of the transgenic mice, we concluded that 27-OH 
is not a general activator of LXR in the brain. 
 
In Paper II, this study has examined the role of 27-OH in the liver using the above three mouse 
models. In the liver of CYP27A1tg mice we found a modest increase of the mRNA levels 
corresponding to the LXR target genes Cyp7b1, and Abca1. There was no effect on a number of 
other LXR-regulated genes. There were no significant effects on cholesterol synthesis at the 
transcriptional level and cholesterol precursors were not affected as well. However, there was a 
modest decrease in T-MAS levels in the liver of CYP27A1tg mice. In the liver of the Cyp7b1-/-mice, 
there were also no effects on cholesterol synthesis neither at the transcriptional level nor in the levels 
of cholesterol precursors, with the exception of increase in desmosterol. In connection to the LXR-
target genes in these mice, there were no differences in the expression between the Cyp7b1-/- and the 
wild type mice. If the high levels of 27-OH are important, the same effects would be expected in the 
two mouse models. In the liver of the Cyp27a1-/-  mice there was a slight activation of some LXR- 
regulated genes, Abcg5, Abcg8, Fas and Srebp1c. If 27-OH is of importance as a normal activator of 
the above genes a suppressing effect would be expected. The overall results do not support the 
contention that 27-OH is an important regulator of cholesterol homeostasis or an activator of LXR-
regulated genes under basal conditions in the liver. 
 
In conclusion our results suggest that both 24S-OH and 27-OH may be of some regulatory 
importance for cholesterol synthesis in the brain but not in the liver. Under normal basal conditions 
27-OH does not seem to be a general activator of LXR neither in the brain nor in the liver. The 
different effects on cholesterol synthesis in the two organs may be related to the fact that almost all 
oxysterols in the brain are in the free form whereas most of them are esterified in the liver. 
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1 BACKGROUND 
1.1 CHOLESTEROL 
Cholesterol is a hydrophobic molecule with the molecular formula C27H45OH and four 
rings in its structure (Figure 1). It is a vital structural component of all mammalian cell 
membranes that is necessary for proper membrane permeability and fluidity. In 
addition to that cholesterol functions as an important precursor for the biosynthesis of 
steroid hormones and bile acids. 
 
 
Figure 1. The Chemical structure of cholesterol molecule. 
 
1.1.1 Cholesterol synthesis and its regulatory mechanisms 
Cholesterol is synthesized by almost all types of mammalian cells, in particular in liver 
and intestine (Dietschy et al., 1993). Cholesterol synthesis occurs in five main steps: 1) 
Condensation of three acetyl-CoA molecules to form 3-hydroxy-3-methyl-glutaryl-
CoA (HMG-CoA) (Bloch, 1987); 2) Conversion of HMG-CoA to mevalonate. This 
reaction is catalyzed by the enzyme HMG-CoA reductase (HMGCR), which is the rate 
limiting step in the cholesterol synthesis pathway (Goldstein and Brown, 1990); 3) 
Formation of the five carbon structure isopentenyl-PP from mevalonate. Isopentenyl-
PP is the precursor not only for cholesterol but also for many non-steroidal isoprenoid 
molecules that are of importance for prenylation of different proteins within the cell; 4) 
Generation of the 30 carbon atom structure squalene from the isopentenyl-PP through 
multiple steps; 5) conversion of squalene into lanosterol, which is then converted to 




Figure 2. A simplified overview of cholesterol biosynthesis. Cholesterol synthesis also results in 
production of non-steroidal isoprenoid molecules (geranyl geranol-PP). PP; pyrophosphate. 
 
Cholesterol biosynthesis, uptake and turn-over by the cells are among the most strongly 
regulated processes in the cells. The rate limiting enzyme in cholesterol biosynthesis, 
HMGCR, is competitively inhibited by the cholesterol lowering drug statin (Stancu and 
Sima, 2001). Sterol regulatory element binding proteins (SREBPs) are ER membrane-
bound transcription factors able to regulate multiple genes involved in cholesterol and 
fatty acids biosynthesis and uptake (Brown and Goldstein, 1999). There are three 
isoform of SREBPs. SREBP-1a and SREBP-1c are produced by the same gene and 
mainly control genes involved in the fatty acid synthesis. SREBP-2 is encoded by a 
separate gene and controls the transcription of genes involved in cholesterol synthesis 
(e.g. HMGCR) and uptake (low density lipoprotein-receptor (LDL-R) ) (Brown and 
Goldstein, 1997). In the ER membrane, SREPB-2 is bound to the SREBP-cleavage 
activating protein (SCAP) which forms a complex with the anchor protein insulin-
induced gene (Insig) in the presence of high cholesterol concentrations. SCAP serves as 
a cholesterol level sensor due to the presence of a specific intra-membrane sequence 
called sterol sensing domain (SSD). When cholesterol levels drop in the cell, the 
SREBP-2/SCAP complex is released from the anchor protein Insig and transported to 
the Golgi, where it is subjected to enzymatic cleavage by two proteases with 
subsequent release of the active form of SREBP-2. The latter compound enters the 
nucleus and exerts its action by binding to the sterol regulatory elements (SREs) in 
target genes (Goldstein et al., 2006) (Figure 3). 
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Figure 3. Schematic picture of the SREBP pathway. In the ER membran, SREBP forms a complex with 
an escort protein called SCAP that facilitates the transportation of SREBP from the ER to the Golgi 
where two proteases, S1P and S2P, act on the SREBP/SCAP to release the active transcription factor 
domain of the SREBP from the membrane. This transcription factor domain is then translocated to the 
nucleus and enters the nucleus and activates genes encoding enzymes required for the synthesis of 
cholesterol and fatty acids through binding to the SRE. This process is blocked by cholesterol and 
oxysterols, so when the levels of cholesterol or oxysterols are sufficient in the cell, the anchor protein 
Insig binds to the SREBP/SCAP complex and prevents its movement to the Golgi. 
 
HMGCR has a sterol sensing domain (SSD) similar to that in SCAP. When the 
concentration of sterols increases in the ER, this will induce binding of the reductase 
enzyme to the ER proteins Insig-1 and Insig-2. This will lead to recruitment of a 
membrane-associated ubiquitin ligase that initiates ubiquitination and subsequent 
degradation of the HMGCR (Sever et al., 2003). The cholesterol synthesis pathway can 
also be rapidly regulated by phosphorylation and dephosphorylation of the enzyme 
HMGCR. This enzyme is most active in its unmodified form and phosphorylation by 
adenosine monophosphate protein kinase (AMK) decreases its activity (Corton et al., 
1994; Hardie, 2003). 
 
1.1.2 Cholesterol absorption and transportation 
Cholesterol is a hydrophobic molecule, which must be associated with lipoproteins to 
enable its transport in the blood stream. Dietary cholesterol is absorbed from the 
intestinal lumen and delivered to the liver by chylomicrons. In the liver cholesterol may 
be stored as cholesteryl esters, by the action of the enzyme acyl coenzyme A: 
cholesterol acyltransferase (ACAT), converted to bile acids, secreted directly in the bile 
or packed in the very low density lipoprotein (VLDL) particles. In the circulation, the 
triglyceride core of VLDL is subjected to lipolysis by the lipoprotein lipase and there is 
a transfer of apolipoproteins A and C to HDL. Eventually, hydrolysis of VLDL 
remnants by hepatic lipase will lead to formation of low density lipoprotein (LDL), 
which contains relatively high cholesterol content. LDL delivers cholesterol to target 
tissues through interaction with the LDL-R. 
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1.1.3 Cholesterol elimination 
Free cholesterol is toxic for the cells and is converted to cholesterol esters by the action 
of the enzyme ACAT in the cells and by the enzyme lecithin: cholesterol 
acyltransferase (LCAT) in the circulation. The unesterified cholesterol is transported to 
the liver in the HDL particles. Lipidation of HDL is facilitated by the transmembrane 
ATP-binding cassette transporter (ABCA1). The HDL is then taken up by the liver, 
where the cholesterol is metabolized. The flux of excess cholesterol from the peripheral 
tissues to the liver by HDL is called reverse cholesterol transportation (RCT). 
 
Another major route for elimination of excess cholesterol from the body is by being 
secreted into the bile (via ABCG5/ABCG8) as free cholesterol for subsequent 
elimination in the faeces (Graf et al., 2003). 
 
Extrahepatic tissues can also convert cholesterol into hydroxycholesterol by the action 
of the cytochrome P-450 enzyme CYP27A1 (cf. below). This 27-hydroxylation of 
cholesterol allows a rapid passage through the cell membrane followed by 
transportation in the lipoproteins back to the liver. 
 
 
1.2 BILE ACIDS 
Bile acids are necessary for emulsification and absorption of dietary lipids, cholesterol 
and lipid-soluble vitamins in the intestine. The synthesis of bile acids takes place in the 
liver, where approximately 500 mg of cholesterol is converted into bile acids daily. 
After secretion of the bile into the intestine about 95% of the bile acids are reabsorbed 
and get back to the liver in what is called enterohepatic circulation. About 300-500 mg 
of bile acids avoids this cycle and are excreted in the faeces daily. The liver compensate 
for this loss by replacing it with a newly synthesized bile acids (~500mg/day) and this 
is one of the two major mechanisms to eliminate excess cholesterol from the body. 
 
The process of bile acid synthesis involves multiple enzymes and takes two major 
pathways, the classical (neutral) and the alternative (acidic) (Russell, 2003). The first 
step in the classical pathway is catalyzed by the rate limiting enzyme cholesterol 7α-
hydroxylase (CYP7A1) resulting in the production of cholic acid (CA) and 
chenodexoycholic acid (CDCA) with CA as the major product. In the alternative 
pathway CDCA is formed predominantly. 
 
The alternative pathway is initiated by the sterol 27-hydroxylase (CYP27A1) and is 
believed to contribute to about 25% of the formation of bile acids in rodents. Knocking 
out the gene Cyp27a1 in mice results in a severe reduction of bile acid synthesis (by 
about 70%). As a consequence of the decreased levels of bile acids, these mice also 
show decreased intestinal cholesterol absorption and increased cholesterol synthesis. As 
a compensatory mechanism, Cyp7a1 is upregulated in the mutant mice (Rosen et al., 
1998; Repa et al., 2000). Feeding with cholic acids normalizes the metabolic 
disturbance in these mice. Unlike mice a mutation in the human gene CYP27A1 results 
in accumulation of xanthomas in the brain and tendons. This rare disease is called 
cerebrotendinous xanthomatosis (CTX) and is also characterized by dementia, ataxia 
and cataracts (Bjorkhem and Leitersdorf, 2000). 
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The bile acid pool is auto-regulated by the binding of bile acids to the nuclear receptor 
farnesoid X receptors (FXR) in the liver (Makishima et al., 1999; Chiang, 2004). FXR 
inhibits CYP7A1 transcription by a mechanism involving activation of small 
heterodimer (SHP) and liver receptor homologue 1 (LRH1). Bile acids fluxing into the 
intestine regulate the plasma levels of intestinal fibroblast growth factor (FGF) 19 (in 
mice FGF15)  that in turn regulate the activity of the enzyme CYP7A1 (Inagaki et al., 
2005; Lundasen et al., 2006). 
 
 
1.3 CHOLESTEROL METABOLISM IN THE BRAIN 
The brain is very rich in cholesterol and its total cholesterol content is estimated to be 
about 25% of the total cholesterol in the body. Almost all of it exists as unesterified 
cholesterol. Most of the brain cholesterol is localized to myelin (about 70%). The 
myelin sheath is essential for the proper functioning of the brain. Unlike other tissues in 
the body, the brain cholesterol pool is totally isolated from other pools in the body due 
to the presence of the blood-brain barrier which is impermeable to lipoprotein-bound 
cholesterol in the circulation. All cholesterol found in the brain is thus synthesized in 
situ. Oligodendrocytes, the cells responsible for myelination, and astrocytes are the 
major cells responsible for cholesterol synthesis in the brain (Bjorkhem and Meaney, 
2004). 
 
Cholesterol synthesis in the brain is relatively high during the development period but 
reaches a very low level in the adult state. As a consequence, the cholesterol in the 
adult human brain has a long half-life that approximated to be five years (Bjorkhem et 
al., 1998; Dietschy and Turley, 2004). In spite of this long half-life, the brain still needs 
to eliminate some of its cholesterol to maintain constant levels. About 1 – 2 mg/day of 
apolipoprotein E-bound cholesterol (APOE) is excreted from the brain into the 
cerebrospinal fluid (CSF). However, the conversion of cholesterol into 24S-OH is 
considered to be the quantitatively major mechanism for elimination of the excess 
cholesterol from the brain (cf. below). The amount of cholesterol eliminated from the 
human brain through this pathway is estimated to be about 6-7mg/day (Bjorkhem et al., 
1998). 
 
Neuronal cells are able to synthesize cholesterol but this synthesis is reduced during its 
maturation. Therefore neurons are dependent on cholesterol provided by astrocytes 
(Pfrieger, 2003). Astrocytes are also considered to be the main producer of APOE in 
the brain, which is the main transporter protein for cholesterol in the central nervous 
system. APOE-bound cholesterol is taken up by the neurons and other cells via LDL-R 
and LDL receptor-related protein (LRP). Astrocytes also express the membrane 
transporter ABCA1, which is also important for cholesterol flux in the brain (Bjorkhem 
and Meaney, 2004). 
 
 
1.4 SIDE-CHAIN OXIDIZED OXYSTEROLS 
Oxysterols were first identified by Lifschütz about one century after the 
characterization of cholesterol. They are oxygenated derivatives of cholesterol and can 
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be formed enzymatically and non-enzymatically. They are characterized by very short 
half-life and ability to pass lipophilic membranes more easily than cholesterol. The 
latter property makes them easily redistributed in the body (Lange et al., 1995; Meaney 
et al., 2002). In particular this is valid for side-chain oxidized oxysterols like 24S-
hydroxycholesterol (24S-OH), 27-hydroxycholesterol (27-OH) and 25-
hydroxycholesterol (25-OH). Due to these physical property oxysterols are considered 
as important intermediates in cholesterol excretion pathways and conversion to bile 
acids.  
 
The two major oxysterols in the circulation of man and rodents are 24S-OH and 27-OH 
(Bjorkhem, 2009). 24S-OH is formed by the enzyme cholesterol 24-hydroxylase 
(CYP46A1) that is located almost exclusively to the brain in humans (Bjorkhem et al., 
1998; Lund et al., 1999). Unlike cholesterol, this mono-oxygenated molecule is able to 
cross the BBB to the circulation, where it is taken up by the liver and converted into 
bile acids and conjugates of un-metabolized or partially metabolised 24S-OH 
(Bjorkhem et al., 2001). Conversion of cholesterol into 24S-OH is considered to be the 
main mechanism for the elimination of excess cholesterol from the brain in both man 
and rodents. 
 
27-OH is formed by the action of the mitocondirial enzyme sterol 27-hydroxylase 
(CYP27A1) that is widely distributed all over the body. There is a constant flux of 27-
OH and metabolites of this oxysterol from extra-hepatic tissues to the liver where it is 
metabolized into bile acids (Lund et al., 1996). There is a significant uptake of 27-OH 
by the brain where it is rapidly metabolized into a steroid acid, 7α-hydroxy-3-oxo-4-
cholestenoic acid (Heverin et al., 2005). This acid is also able to cross the blood-brain 
barrier and is rapidly eliminated from the brain and metabolized in the liver (Meaney et 
al., 2007). 
 
1.4.1 Regulatory roles of the side-chain oxidized oxysterols in 
cholesterol homeostasis 
Under in vitro conditions, side-chain oxidized oxysterols are able to regulate critical 
genes in cholesterol turnover pathways. As mentioned above, cholesterol synthesis is 
regulated by the controlled movement of SREBP from the ER to the Golgi, where it is 
subjected to a series of cleavage with subsequent release of the active form and its 
translocation into the nucleus. This movement is inhibited by either cholesterol itself or 
oxysterols, thus stopping cholesterol synthesis. Cholesterol induces conformational 
changes in SCAP and as a consequence SCAP binds to Insig. On the other hand, 
oxysterols inhibit cholesterol synthesis by binding to Insig followed by binding of Insig 
to SCAP. The latter binding prevents the transportation of the SREBP/SCAP complex 
to the Golgi (Radhakrishnan et al., 2007). Side-chain oxidized oxysterols can also 
induce formation of the HMGCR/Insig complex that leads to ubiquitination and 
degradation of the enzyme resulting in a rapid inhibition of cholesterol (Sever et al., 
2003; Goldstein et al., 2006). It has been reported that 27-OH enhance HMGCR 
ubiquitination and degradation under in vitro conditions (Radhakrishnan et al., 2007). 
It should be emphasized that the above mechanisms for regulation of cholesterol 
homeostasis have been demonstrated in vitro and the importance of oxysterols in 
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regulation of cholesterol homeostasis in vivo in the presence of great excess of 
cholesterol, is not known with certainty. 
 
Some of the oxysterols effects on cholesterol homeostasis are believed to be mediated 
by the nuclear liver X receptor (LXR). There are two isoforms LXRα and LXRβ that 
form a heterodimer with the retinoid X receptors (Willy et al., 1995). LXRs have an 
important physiological role in cholesterol and lipid homeostasis as shown by several 
studies in mice lacking LXR (Peet et al., 1998; Schuster et al., 2002). In rodents, 
pharmacological activation of LXR results in an upregulation of Srebp-1c, Fas, Abca1, 
Abcg5, Abcg8, Cyp7a1  and a decrease in Cyp7b1 (Uppal et al., 2007). Activation of 
the LXR-target genes (ABCA1, ABCG5, ABCG8, and CYP7A1) can be regarded as a 
defence mechanism preventing accumulation of cholesterol in tissues. 
 
Lehmann et al. demonstrated that oxysterols are natural ligands for LXR under in vitro 
conditions (Lehmann et al., 1997). It has been found that 24(S), 25-epoxycholesterol, 
24S-OH, and 25-OH are the most potent LXR-activating oxysterols. 27-OH is a less 
potent activator of LXR than the aforementioned oxysterols but this oxysterols is 
however, present at relatively high levels and  has therefore been suggested as a 
physiological activator of LXR. Several in vitro studies have demonstrated the ability 
of 27-OH to activate the LXR-responsive genes, ABCA1, ABCG1and APOE (Kim et 
al., 2009). Fu and his colleagues also reported that 27-OH is an activator of ABCA1 
and ABCG1 genes in cholesterol-loaded fibroblast (Fu et al., 2001). 
 
Oxysterols are present in trace amounts only in the circulation and tissues and is always 
accompanied by 103- to 106- fold excess of cholesterol. In most tissues this excess of 
cholesterol in relation to oxysterol, might affects the binding ability of oxysterols to 
LXR (Bjorkhem, 2009). In the brain, however, the ratio between a side-chain oxidized 
oxysterol and cholesterol is higher than 1 to 1000. Therefore there is a higher potential 
for LXR-mediated regulation in the brain than in other tissues. 
 
Neurons are believed to depend on astrocytes for their cholesterol supply that is 
delivered in an APOE-bound form. Based on in vitro studies, it has been postulated by 
Pfrieger that the flux of cholesterol from astrocytes to neurons is regulated by 24S-OH, 
which is considered as one of the most efficient activators of LXR in vitro. Flux of 
24S-OH from the neurons to the astrocytes would be expected to results in transcription 
of the LXR-target genes ABCA1and APOE in glial cells with subsequent increase in 
cholesterol efflux (Pfrieger, 2003). This contention is supported by another in vitro 
experiment demonstrating that 24S-OH induces expression of APOE and APOE-
mediated efflux of cholesterol via an LXR pathway (Abildayeva et al., 2006). 
 
1.4.2 In vivo studies in mice with different levels of side-chain oxidized 
oxysterols 
More than 30 years ago, based on in vitro studies, it was hypothesized that oxysterols 
are important physiological regulators of cholesterol homeostasis (Kandutsch et al., 
1978). Since then, many in vitro and in vivo studies have been done to test the validity 
of the hypothesis. The important role of oxysterols in bile acid synthesis and in 
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cholesterol transportation is well documented. However their physiological role as 
regulators of cholesterol homeostasis in vivo is still unclear. 
 
Experiments on mice lacking the enzyme Cyp46a1 revealed a reduction in cholesterol 
biosynthesis in the brain of the mutant mice by about 40%, but not in other organs 
(Lund et al., 2003). This reduction in cholesterol synthesis is mainly due to reduced 
elimination of cholesterol from the brain by its conversion into 24S-OH. In spite of this, 
the total cholesterol levels in the brain of the mutant mice are normal.  The effect of the 
knocking-out of the enzyme Cyp46a1 on LXR-target genes in the brain was not 
studied. Behavioral studies in these mice demonstrate severe memory defects (Kotti et 
al., 2006). 
 
A transgenic mouse model with high levels of 24S-OH has been recently generated by 
our group (Shafaati et al., 2011). These mice are overexpressing the human enzyme 
CYP46A1 that consumes cholesterol and converts it to 24S-OH. The over expression 
induces cholesterol synthesis in these mice with unchanged cholesterol levels in the 
brain. It is known from in vitro studies that 24S-OH is one of the most efficient LXR 
activators (Janowski et al., 1999). Contrary to expectations, there were no stimulatory 
effects on the LXR-target genes in the brain and liver of these transgenic mice (Shafaati 
et al., 2011). These results are consistent with other results acquired by local over 
expression of CYP46A1 in the cortex and hippocampus of APP23 mice. This group 
also failed to detect any activation of LXR-target genes in the brain of these mice in 
spite of the elevated 24S-OH (Hudry et al., 2010). 
 
Knocking-out the enzyme ( Cyp27a1) responsible for the formation of  27-OH in mice 
results in approximately a 75% decrease in bile acid pool, reduced intestinal cholesterol 
absorption and increased hepatic cholesterol synthesis. Cholic acid supplementation of 
the diet of these mice reverses all these symptoms (Repa et al., 2000). In a separate 
study by our group, we found that these mice have a modest upregulation of cholesterol 
synthesis in the brain as predicted by high lathosterol levels (Bavner et al., 2010). This 
increase in cholesterol synthesis is observed in the brain of mice treated with cholic 
acid as well as in non-treated mice. This result is consistent with a possible regulatory 
role of 27-OH for cholesterol synthesis in the brain. However, the effects of the 
knocking-out of the gene on LXR-target genes were not studied in this model. 
 
Overexpression of the human CYP27A1 in mice results in 3-5 fold increase in 27-OH 
in the circulation and tissues. There is no marked effect on cholesterol homeostasis in 
these mice (Meir et al., 2002). The most striking effect in these mice is the reduced 
levels of 24S-OH in the circulation of the overexpressor mice, possibly due to 
metabolism by the overexpressed enzyme (Bjorkhem et al., 2001). Disruption of 
oxysterol 27-hydroxylase (Cyp7b1) in mice also results in markedly high levels of 27-
OH in the circulation and tissues (Li-Hawkins et al., 2000). These mice have normal 
cholesterol levels in the circulation and normal cholesterol synthesis in the liver. The 
possible consequences of the high levels of 27-OH on the expression of LXR-target 
genes were never studied in any of these two models. 
 
A triplet knock-out mouse model that lacks 24S-OH, 25-OH and 27-OH in the 
circulation and tissues was generated previously (Chen et al., 2007). Due to the 
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consequences of the knock-out of Cyp27a1, the mice were treated with cholic acid in 
diet. Challenging these mice with high cholesterol diet failed to induce expression of 
some established LXR-target genes in the liver. This result led to the conclusion that 
some of the effects of cholesterol feeding on LXR-target genes are likely to be 
mediated by side- chain oxidized oxysterols. 
 
The above in vivo studies do not support the contention that side-chain oxidized 
oxysterols are important for cholesterol synthesis and turnover under normal 
conditions, with the possible exception of the situation in the brain. Except for the 
situation with high levels of 24S-OH, the effects of high levels of side-chain oxidized 
oxysterols on LXR-targeted genes have not been studied previously. 
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2 AIMS 
The intention of the present study was to use transgenic mouse models with markedly 
changed levels of side-chain oxidized oxysterols to evaluate if such oxysterols are of 
importance in the regulation of cholesterol homeostasis and LXR-target genes in the 
brain (Paper I) and in the liver (Paper II). 
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3 MATERIALS AND METHODS 
The following is a brief account of materials and methods used in this thesis. For more 




All the mice were between 2-4 months old when experiments were conducted. The 
mice were specifically generated for these experiments from our on-going breeding 
colonies in Huddinge University Hospital Animal Facility. The colonies were 
maintained by breeding heterozygous pairs. The animals were housed under standard 
environmental conditions with free access to food and water. All the mice were 
euthanized by CO2 inhalation at the same time in the morning except Cyp27a1 knock-
out mice, which were euthanized by cervical dislocation. Blood and tissues were 
collected and stored at -80°C. 
 
All experiments in these studies were performed in accordance with the guide lines 
from the Swedish national board for Laboratory Animals and the European 
Communities Council Directive of 24 November 1986 (86/609/EEC), and approved by 
the Southern Stockholm Ethical Committee. 
 
3.1.1.1 CYP27A1 transgenic mice (CYP27A1 tg) 
These mice were generated previously using the b-actin promoter (Meir et al., 2002). 
The founders were originally obtained from our collaborator Eran Leitersdorf and they 
were on C57BL/6 background. In this experiment C57BL/6 mice were used as a 
control group and they were purchased from Charles River Laboratories, Germany. 
 
3.1.1.2 Cyp27a1 knock-out mice (Cyp27a1-/-) 
This strain was also generated previously on C57BL/6 background (Rosen et al., 1998). 
Homozygous knock-out mice and their corresponding wild type controls were 
generated from breeding of heterozygous mice. The diet of the mice was supplemented 
with 0.05% cholic acid at the age of 6 weeks. This supplementation compensates for 
the reduced bile acid synthesis in these mice (Repa et al., 2000). 
 
3.1.1.3 Cyp7b1 knock-out mice (Cyp7b1-/-) 
The Cyp7b1-/- mice used in this project were generated in another laboratory as has 
been described previously (Rose et al., 2001). They were on C57BL/6 background. In 
the same way as for Cyp27a1-/- mice, homozygous knock-out mice and their 







3.2.1 Lipid extraction and analysis 
Livers and brains were extracted according to Folch method. Folch solution 
(chloroform/methanol 2:1,v:v), 3 and 10 ml, were added to about 100 mg liver tissue 
and half of a brain or a hippocampus or a cortex from half of a brain, respectively. After 
24 hours at room temperature extracts were transferred to new vials and evaporated 
under argon. After evaporation the extracts were re-dissolved in 1 ml Folch (liver) or 
10 ml Folch (brain) and stored at -20°C until required. Sterols and oxysterols were 
measured in the Folch extract by gas chromatography–mass spectrometry after alkaline 
hydrolysis using deuterium-labelled internal standards as previously described 
(Dzeletovic et al., 1995; Acimovic et al., 2009). In some experiments the hydrolysis 
step was excluded in order to measure the fraction of unesterified oxysterol. 
 
3.2.2 RNA preparation and real-time PCR 
Total RNA was extracted from liver and brain tissues by TRIzol reagent. 1 µg of total 
RNA was used for the cDNA synthesis. The relative expression levels of target genes 
were determined by Fast Real-time PCR System (Applied Biosystems). All values were 
normalized to Hypoxanthine phosphoribosyltransferase (HPRT) mRNA concentrations. 
 
3.2.3 Statistics 
Measurements of mRNA are shown as mean ± range as described by Livak and 
Schmittgen (Livak and Schmittgen, 2001). Determinations of sterols are shown as 
mean ± SEM. Statistical analysis was done using the unpaired Student t-test. 
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4 RESULTS AND DISCUSSION 
 
4.1 ON THE REGULATORY ROLE OF SIDE-CHAIN HYDROXYLATED 
OXYSTEROLS IN THE BRAIN. LESSONS FROM CYP27A1 
TRANSGENIC AND CYP27A1-/- MICE (PAPER I) 
4.1.1 Effects of overexpression and knocking-out of the gene CYP27A1 
on cholesterol synthesis 
The plasma and brain levels of 27-OH were about 6- and 11- fold higher in the 
transgenic mice than in the controls, respectively. 27-OH is a suppressor of cholesterol 
synthesis under in vitro conditions. Therefore we would expect a suppression of 
cholesterol synthesis in the brain of the transgenic mice. There was, however, an 
increase in cholesterol synthesis in the brain of the CYP27A1tg mice as shown by the 
elevated mRNA levels of Hmgcr, Hmgcs and Srebp2 in the brain of the CYP27A1 
transgenic male mice (Figure 4d). In accordance with this, most of the cholesterol 
precursors in the brain of these mice were also increased (Figure 4a).  
 
There was an approximate 25% reduction in the major cerebral oxysterol 24S-OH. It 
has been demonstrated previously that 24S-OH is metabolized by CYP27A1 
(Bjorkhem et al., 2001), which could be the cause of the low levels of 24S-OH. It is 
most likely that this reduction in the levels of 24S-OH, which is known to be a 
suppressor of cholesterol synthesis in neuronal cells (Wang et al., 2008), is the reason 
for the increased cholesterol synthesis. In spite of the high levels of 27-OH in the brain 
of transgenic mice compared to the controls, the levels are still much lower than the 
concentration of 24S-OH in the brain.  
 
There is another possibility that the increased cholesterol synthesis in the brain of the 
transgenic mice is a compensatory mechanism due to the increased consumption of the 
brain cholesterol by the overexpressed enzyme. It seems less likely that such a 
metabolic pathway could be of major importance, since the normal expression of 
CYP27A1 in the brain is low and it is believed that most of the cerebral 27-OH 
originates from the circulation (Heverin et al., 2005). There was no tendency to reduced 
levels of cholesterol in the CYP27A1 transgenic mice (Figure 4a).  
 
Knocking-out the Cyp27a1 gene also resulted in increased cholesterol synthesis in the 
cortex of the brain of the Cyp27a1-/- mice as judged by increased cholesterol precursors 
(Figure 4c). This result is consistent with the result of a previous work on the brain of 
this model (Bavner et al., 2010). The most likely explanation for the increased 
cholesterol synthesis in these mice is the lack of normal flux of 27-OH into the brain 
that has a slight inhibitory effect on cholesterol synthesis. It should be pointed out that 
these mice were treated with cholic acid to compensate for their reduced bile acid 
synthesis. In theory bile acid on itself could have some effects on cholesterol 
homeostasis in the brain. In the previous work, however, the same results were obtained 
both with treated and un-treated mice with cholic acid. 
 
 14 
4.1.2 Theoretical model for regulation of cholesterol homeostasis in the 
brain 
The main players in the regulation of cholesterol homeostasis in the brain seem to be 
HMGCR and CYP46A1. Similar to the situation in the liver, HMGCR is subjected to a 
tight regulation in the brain in order to keep the cerebral cholesterol pool at a constant 
level. On the other hand, CYP46A1 is subjected to a very little regulation at the 
transcriptional level (Ohyama et al., 2006). Combining the present results with the 
previous results (Lund et al., 2003; Wang et al., 2008; Bavner et al., 2010; Shafaati et 
al., 2011), we arrived to the regulatory model shown in figure 5. This model is 
consistent with all present results, in vivo and in vitro, but further studies may be 
needed for confirmation.  
 
Given the fact that 24S-OH is a substrate for the enzyme CYP27A1, we believe that the 
increased activity of this enzyme is the explanation for the reduced levels of 24S-OH 
seen in the brain and the circulation of our mouse model. It should be emphasized that 
the reduced levels of 24S-OH in the brain may be the consequence not only of an 
increased metabolism in the brain but also outside the brain (Figure 5). Reduced levels 
of 24S-OH in the circulation lead to an increased concentration gradient of the 
oxysterol between the brain and the circulation, which may lead to increased flux from 
the brain. 
 
After publication of the above results, additional support has been obtained for the 
contention that the level of 24S-OH in the brain is of importance for cholesterol 
synthesis in this organ. In a recent unpublished study, our group characterized 
cholesterol homeostasis in the brain of a mouse model with pericyte-deficiency 
resulting in a leaking blood-brain barrier (Saeed et al, unpublished study). The 
defective blood-brain barrier resulted in a flux of cholesterol from the circulation into 
the brain and an increased flux of 24S-OH from the brain into the circulation. The latter 
flux leads to a reduction in the level of 24S-OH in the brain that was similar to the 
reduced levels of 24S-OH in the brain of our CYP27A1tg mice. Also in this case the 
reduced levels of 24S-OH were associated with increased cholesterol synthesis in the 
brain. If the increased levels of 27-OH in the brain of CYP27A1tg mice had been the 
reason for the increased cholesterol synthesis, the same effect would have been 
expected in the brain of Cyp7b1-/- mice. However, neither cholesterol synthesis genes 
nor cholesterol precursors (Figure 4b), were affected by the high levels of 27-OH in 
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Figure 4. The effects of 27-OH on the cholesterol synthesis and LXR-target genes in the adult brain of 
male mice from different mouse models. (a), the effect of overexpression of human CYP27A1 on the 
levels of cholesterol and cholesterol precursors in the brain of CYP27A1 transgenic mice; (b) levels of 
cholesterol and cholesterol precursors in the  brain of Cyp7b1 knock-out mice; (c) levels of cholesterol 
and cholesterol precursors in the  brain of Cyp27a1 knock-out mice; (d) mRNA levels of SREBP-
regulated and LXR-regulated genes in the brain of CYP27A1 transgenic mice. n = 7-10 in each 




Figure 5. Theoretical model for the regulation of cholesterol homeostasis in the brain.  
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4.1.3 Effects of overexpression and knocking-out of the gene Cyp27a1 
on LXR-targeted genes 
In contrast to our expectation the overexpression of CYP27A1 led to moderate changes 
only in the expression of LXR targeted genes. Some of the LXR target genes (Abcg1, 
Abca1, and Srebpc1) were slightly decreased by the overexpression rather than 
increased. On the other hand, there were no changes on the LXR-target genes in the 
brain of the Cyp27a1-/- mice. 
 
It has been reported that sulphatation of 25-OH is an antagonist mechanism for the 
oxysterol-dependent activation of the LXR (Xu et al., 2010). Therefore we considered 
the possibility that the opposite effect on LXR target genes that we observed could be 
due to a sulphated form of 27-OH. In a very recent study from our laboratory we found 
that the fraction of the total level of  the sulphated 27OH in the CYP27A1tg mice is 
similar to that in the wild-type mice (Acimovic et al., 2013). Thus it is seems less likely 
that 27OH sulphate is of importance for the effects observed. 
 
An alternative explanation is that reduction in the pool of 24S-OH is the cause of the 
above opposite effect, since 24S-OH is an efficient activator of LXR in vitro. In a 
previous study on mice with high levels of 24S-OH in the brain, there was a normal 
expression of the LXR-target genes in the brain (Shafaati et al., 2011). The same result 
was obtained from another recent study on the pericyte deficient mouse model that 
have reduced levels of 24S-OH in their brain (Saeed et al, unpublished study). The 
results from these two studies do not support the hypothesis that the reduced level of 
24S-OH is the cause of the downregulation of LXR-target genes observed in the brain 
of the transgenic mice.  
 
In conclusion our data in this study does not support the contention that 27-OH and 
24S-OH are important activators of LXR in the brain, at least not under normal 
conditions. It seems likely, however, that 24S- and 27-OH have a suppressive effect on 
cholesterol synthesis in the brain.  
 
4.2 ON THE REGULATORY IMPORTANCE OF 27-
HYDROXYCHOLESTEROL IN MOUSE LIVER (PAPER II) 
4.2.1 Effects of 27-OH on cholesterol synthesis in the liver 
It has been shown that 27-OH is a strong inhibitor of cholesterol synthesis under in 
vitro conditions (Axelson and Larsson, 1995; Schroepfer, 2000). In this study we were 
interested to investigate the effect of 27-OH on cholesterol synthesis and LXR-target 
genes in vivo, particularly in the liver. We used two mouse models (Cyp7b1-/- and 
CYP27A1tg mice) with high levels of 27-OH in their circulation and liver, plus a 
model with undetectable levels of 27-OH in the circulation (Cyp27a1-/- mice). The 
advantage of using two different models with high levels of 27-OH is that, any effect 
due to 27-OH itself should be seen in both models. 
 
There was no downregulation of cholesterol synthesis in the liver of Cyp7b1-/- and 
CYP27A1tg mice as judged by normal mRNA levels of cholesterol synthesis genes 
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(Hmgcr, Hmgcs and Srebp2) as well as normal levels of most cholesterol precursors in 
the liver (Figures 6 & 7). 
 
Our results are in agreement with the previous results (Li-Hawkins et al., 2000), where 
they failed to detect effects on cholesterol synthesis in the liver of Cyp7b1-/- mice. The 
results are also consistent with the previous work in our laboratory, in which a trial to 
demonstrate a critical role of the 24S-, 25 or 27-hydroxycholesterol for cholesterol-
induced downregulation of Hmgcr in mouse liver failed (Lund et al., 1992). 
 
4.2.2 Effects of 27-OH on LXR-targeted genes in the liver 
27-OH is less potent than 24S-OH in activation of the LXR mechanism. However, it is 
present at a higher concentration than 24S-OH in the circulation and all tissues apart for 
the brain and this increases it’s potential to stimulate LXR. Since there were high levels 
of this oxysterol in the circulation and the liver of the Cyp7b1-/- and CYP27A1tg mice, 
we expected a possible upregulation of the LXR-targeted genes in these mice. There 
were no effects in the liver of the Cyp7b1-/- mice, while there was a slight upregulation 
of the genes Abca1 and Cyp7b1 in the CYP27A1tg mice. If such an effect is due to the 
high levels of 27-OH, it should be seen in both models. Activation of LXR would result 
in inhibition of the gene Cyp7b1 rather than activation (Uppal et al., 2007). A previous 
study by our group (Shafaati et al., 2011) also failed to demonstrate any activation of 
LXR-target genes in the liver of CYP46tg mice in spite of the fact that 24S-OH is a 
potent activator of LXR (Janowski et al., 1996). 
 
Unexpectedly, there was an activation of some LXR-targeted genes Fas, Abcg5, Abcg8 
and Srebp1c in the liver of the Cyp27a1-/- mice (Fig. 7). Since these mice were treated 
with cholic acid, we cannot exclude the possibility that this effect could be due to the 
cholic acid rather than to 27-OH. The suppression of the gene Cyp7a1 is most likely a 
secondary effect to the cholic acid feeding. The other explanation for the upregulation 
of the above genes is the existence of an unknown activator of LXR that is normally 
metabolized by Cyp27a1. A lack of this enzyme can then be expected to be associated 
with increased activation of LXR. Further work is needed to discriminate between these 
two possibilities. 
 
Most of the oxysterols in the liver and circulation (90%) are present in the esterified 
form (Dzeletovic et al., 1995; Li-Hawkins et al., 2000). The opposite is observed in the 
brain, where 90% or more of the cholesterol and oxysterols are in the unesterified form. 
We have found that 98% of 24S-OH and 90% of 27-OH in mouse brain are present in 
free form (unpublished observation). The presence of most 27-OH in the esterified 
form, which is believed to be the inactive form of the oxysterols, could be the 
explanation for the failure of 27-OH to exert any effect on cholesterol synthesis and 
LXR in the liver of Cyp7b1-/- and CYP27A1tg mice.  
 
The results from different models suggest that 27-OH is unlikely to be an important 
regulator of cholesterol synthesis and LXR in the liver under basal conditions. However 
the situation might be different under some specific pathological conditions.  
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Figure 6. Levels of cholesterol and cholesterol precursors in the liver of Cyp7b1 knock-out mice (a), 
CYP27A1 transgenic mice (b) and Cyp27a1 knock-out mice (c). n = 7-10 in each experiment. Data are 









Figure 7. mRNA levels of SREBP-regulated and LXR-regulated genes in the liver of Cyp7b1 knock-
out mice (a), CYP27A1 transgenic mice (b) and Cyp27a1 knock-out mice (c). n = 7-10 in each 
experiment. Data are presented as mean ± SEM. * P < 0,05. 
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5 CONCLUSIONS 
Paper I – The results are consistent with the possibility that both 24S-OH and 27-OH 
are modest physiological suppressors of cholesterol synthesis in the brain but not 
important activators of the LXR-target genes in this organ.  
 
Paper II – Using two mouse models with high levels of 27-OH, we failed to 
demonstrate any regulatory role for 27-OH on cholesterol synthesis or on LXR-target 
genes in the liver under normal conditions. 
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